Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 5, 2007, Pages 671-679

  Brown, Alan P ^a   Carlson, Tage C G ^a   Loi, Cho Ming ^a   Graziano, Michael J ^a  

^a PFIZER INC   (United States)

Author keywords

Anticancer; Biomarkers; MAPK

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CARBOXYLIC ACID DERIVATIVE; DRUG METABOLITE; HYDROXYPROPYLMETHYLCELLULOSE; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PD 315209; POLYSORBATE 80; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BLOOD SAMPLING; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; LIVER; LUNG PARENCHYMA; MALE; METABOLITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPRAGUE DAWLEY RAT; TISSUE LEVEL; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BENZAMIDES; DIPHENYLAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLUCURONIDES; HALF-LIFE; INJECTIONS, INTRAVENOUS; LIVER; LUNG; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; OXIDATION-REDUCTION; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33847095086     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0323-5     Document Type: Article

References (19)

1. Allen LF, Sebolt-Leopold J, Meyer MB (2003) CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 30(5 Suppl. 16):105-116
2. Brown AP, Courtney C, Carlson T, Graziano M (2005) Administration of a MEK inhibitor results in tissue mineralization in the rat due to dysregulation of phosphorus and calcium homeostasis. Toxicologist 84(S-1):108 (abstract 529)
3. Dent P, Grant S (2001) Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin Cancer Res 7:775-783
4. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P (1999) Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 91(15):1281-1287
5. Hoshino R, Chatani Y, Yamori T, et al (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase pathway in human tumors. Oncogene 18:813-822
6. Jarvis WD, Auer KL, Spector M, et al (1997) Positive and negative regulation of JNK1 by protein kinase C and p42MAP kinase in adult rat hepatocytes. FEBS Lett 412:9-14
7. Koup JR, Liu J, Loi CM, et al (2004) PK/PD modeling of biomarker (p-ERK) response and tumor growth to PD0325901 in a human tumor xenograft mouse model. Proc Am Assoc Cancer Res 45:1248 (abstract 5409)
8. LoRusso P, Krishnamurthi S, Rinehart JR, et al (2005) A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD0325901 in patients with advanced cancer. Proc Am Soc Clin Oncol (abstract 3011)
9. Luo FR, Yang Z, Dong H, et al (2005) Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the Geo human carcinoma xenograft model. Clin Cancer Res 11(15):5558-5565
10. Mansour SJ, Matten WT, Hermann AS, et al (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265:966-970
11. Mendel DB, Laird AD, Xin X, et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337
12. Milella M, Kornblau SM, Estrov Z, et al (2001) Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108(6):851-859
13. Peralba JM, deGraffenried L, Friedrichs W, Fulcher L, Grunwald V, Weiss G, Hidalgo M (2003) Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887-2892
14. Rinehart J, Adjei AA, LoRusso PM, et al (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22(22):4456-4462
15. Sebolt-Leopold JS (2000) Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19:6594-6599
16. Sebolt-Leopold J (2003) Pfizer Global Research and Development internal publication. Summary of the preclinical pharmacology of PD0325901-0000. RR-REG 761-00063, October 28, 2003
17. Sebolt-Leopold JS, Dudley DT, Herrera R, et al (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5(7):810-816
18. Sebolt-Leopold JS, Merriman R, Omer C, et al (2004) The biological profile of PD0325901: a second generation analog of CI-1040 with improved pharmaceutical potential. Proc Am Assoc Cancer Res 45:925 (abstract 4003)
19. Solit DB, Garraway LA, Pratilas CA, et al (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-362